Dostinex & Generic Cabergoline 0.5mg
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Dostinex & Generic Cabergoline 0.5mg. Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
📖 Peer-Reviewed Clinical Monograph1. Pharmacological Profile & Executive Summary
Potent, long-acting D2 dopamine receptor agonist that directly inhibits pituitary lactotroph prolactin secretion, treating hyperprolactinemia and prolactin-induced sexual dysfunction.
Endocrinology & GLP-1 • Dostinex & Generic Cabergoline 0.5mg
2. Human Pharmacokinetic Matrix
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 2.0 to 3.0 hours | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 63 to 69 hours (supports convenient twice-weekly dosing) | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | 30 to 70 pg/mL (following 0.5mg dose) | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | Significant first-pass hepatic extraction | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 40% to 42% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | Large systemic distribution | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hydrolysis of acylurea bond (minimally dependent on CYP enzymes) | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 72% feces (biliary), 22% urine | Renal vs biliary/fecal excretion balance. |
3. Evidence-Based Clinical Dosing Protocols
Daily / Baseline Regimen
Do NOT take daily. Cabergoline is dosed twice weekly.
On-Demand / Titration Regimen
Hyperprolactinemia / Prolactin-Induced Refractory Period: 0.25 mg to 0.5 mg taken twice weekly (e.g. Monday and Thursday) with food.
Contraindicated in uncontrolled hypertension or cardiac valvular disorders.
4. Pharmacokinetic Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| Dopamine Antagonists (Haloperidol, Metoclopramide) | Antagonistic | Blunts cabergoline therapeutic efficacy. |
| Ergot Alkaloids | Avoid | Additive vasoconstrictive risk. |
5. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Nausea | 15% | Mitigated by taking with dinner at bedtime. |
| Orthostatic Dizziness | 8% | Transient dopamine-mediated vasodilation. |
| Nasal Congestion | 5% | Alpha-adrenergic blockade. |
6. Patient Administration & Safe Usage Guidelines
Always take with food before sleep to prevent nausea. Monitor serum prolactin levels every 4–6 weeks.
7. Frequently Asked Clinical Questions
Why is Cabergoline taken only twice a week?
Cabergoline has an exceptionally long elimination half-life of 65 hours and binds tightly to pituitary D2 receptors, suppressing prolactin for up to 7–14 days per dose.
How does Cabergoline improve male sexual refractory period?
Prolactin is the primary neuroendocrine hormone responsible for post-orgasmic refractory fatigue. Suppressing prolactin shortens recovery time between erections.
Verified Telehealth Access Standards for Dostinex & Generic Cabergoline 0.5mg
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Peer-Reviewed Scientific Citations & FDA References
- Colao A, et al. Cabergoline in hyperprolactinemia. N Engl J Med. 2001;344(11):795-802.